AHF is currently running a TV ad targeting Gilead Sciences for the high drug prices it charges cash-strapped AIDS Drug Assistance Programs (ADAP).
Gilead is the focal point of this ad for obvious reasons – its high prices have left thousands of people without access to lifesaving AIDS treatment. However, they’re not the only drug company gouging ADAP, so why Gilead and why now? Simply put, because Gilead sells more drugs to ADAP than any other company, with Atripla alone accounting for nearly 20% of all ADAP expenditures.
With such a dominant share of ADAP resources, moderate price reductions from Gilead would help generate the savings these programs desperately need. Moreover, given the struggling economy, and the intense pressure on states and Congress to cut spending – not increase it – these reductions are the only way to end the ADAP crisis.
Thankfully for Gilead, this will have no impact on their profits from ADAP, as the cost savings will be used to buy more drugs.
For more information on AHF’s advocacy for lower pricing from Gilead and all the AIDS drug companies, please visit saveadap.org.